Filtered By:
Condition: Thrombosis
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 508 results found since Jan 2013.

Dabigatran "real-life" results suggest caution needed
New data from real-life experience of dabigatran for stroke prevention in AF shows that it is often used outside prescribing recommendations, and the risk of both thromboembolism and bleeding may be raised in patients switched from warfarin.
Source: theHeart.org - May 15, 2013 Category: Cardiology Source Type: news

Dabigatran 'Real Life' Results Suggest Caution NeededDabigatran 'Real Life' Results Suggest Caution Needed
New data from real-life experience of dabigatran for stroke prevention in AF show that it is often used outside prescribing recommendations, and the risk for both thromboembolism and bleeding may be raised in patients switched from warfarin. Medscape Medical News
Source: Medscape Today Headlines - May 15, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Abstract 258: Dabigatran Etexilate is Associated with Shorter Hospital Length of Stay and Lower Hospital Costs Compared to Warfarin in Treatment-Naive, Newly-Diagnosed Nonvalvular Atrial Fibrillation Patients Poster Session III
Conclusions: Among hospitalizations of treatment-naive patients newly diagnosed with nonvalvular AF, the hospitalizations during which DE was administered had a shorter LOS and at least a 12% lower total hospital cost compared to hospitalizations where warfarin was administered.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Fonseca, E., Walker, D. R., Hess, G. P. Tags: Poster Session III Source Type: research

Anticoagulation for non-valvular atrial fibrillation: new anticoagulant agents.
Abstract Atrial fibrillation (AF) is a common cardiac arrhythmia and it is associated with systemic thromboembolism. Until recently, vitamin K antagonists (VKA) such as warfarin were the only available oral anticoagulant therapy for prevention of stroke and systemic embolism in AF. Limitations of VKA therapy have prompted researchers to search for novel anticoagulant drugs, which do not necessitate coagulation monitoring due to their more predictable pharmacokinetic profile. Large-scale phase III trials have been completed for some of these drugs and 'U.S. Food and Drug Administration (FDA)' approved dabigatran an...
Source: The Anatolian Journal of Cardiology - April 11, 2013 Category: Cardiology Authors: Kepez A, Erdoğan O Tags: Anadolu Kardiyol Derg Source Type: research

Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors(June).
CONCLUSIONS:Patients contemplating using the new oral anticoagulants should be informed about specific clinical situations that could pose a bleeding risk such as the need for emergency surgery because no reliable antidote is available to stop the bleeding, which could prove fatal. PMID: 23695644 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - May 21, 2013 Category: Drugs & Pharmacology Authors: Nitzki-George D, Wozniak I, Caprini JA Tags: Ann Pharmacother Source Type: research

Dabigatran: Is There a Role for Coagulation Assays in Guiding Therapy? (June).
CONCLUSIONS:The correlation between coagulation-based assays and clinical outcomes among dabigatran-treated patients has not been definitively established. However, coagulation-based assays may be useful in the management of several clinical scenarios. PMID: 23673530 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - May 14, 2013 Category: Drugs & Pharmacology Authors: Brunetti L, Bandali F Tags: Ann Pharmacother Source Type: research

Supporting the commissioning of anticoagulation therapy for adults
This resource supports commissioners to review how anticoagulation therapy is currently initiated, provided, monitored and reviewed in their local area with particular consideration to the introduction of the novel oral anticoagulants. NICE recommendations for rivaroxaban, dabigatran and apixaban for stroke prevention in people with atrial fibrillation and rivaroxaban for treatment of deep vein thrombosis provide people who have these conditions with more choices of medication. This will have an impact on the commissioning of anticoagulation services at a local level, with an anticipated reduction in vitamin K antagonist monitoring services.
Source: NHS Networks - May 23, 2013 Category: UK Health Authors: Maria Axford Source Type: news

Treatment of Dabigatran-Associated Bleeding: Case Report and Review of the Literature
We report a case involving an 84-year-old male with acute kidney injury who developed life-threatening gastrointestinal and surgical site bleeding secondary to dabigatran accumulation. Use of the Naranjo probability scale indicated a probable cause between the bleeding event and dabigatran use. After discontinuation of drug therapy, fresh frozen plasma, recombinant coagulation factor VIIa, and cryoprecipitate were administered as potential reversal agents with negligible benefit. However, this patient appeared to slowly benefit with administration of continuous venovenous hemodialysis. Based upon our experience with this p...
Source: Journal of Pharmacy Practice - June 5, 2013 Category: Drugs & Pharmacology Authors: Harinstein, L. M., Morgan, J. W., Russo, N. Tags: Adverse Drug Events Source Type: research

Adherence to anticoagulant treatment with dabigatran in a real‐world setting
ConclusionIn our clinical practice adherence to the twice‐daily dabigatran regimen was generally good, although 12% of the patients had an inadequate adherence. Routine feedback from the pharmacies could inform the physician to improve the anticoagulant management.
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: S. Schulman, B. Shortt, M. Robinson, J. W. Eikelboom Tags: Original Article Source Type: research

Managing Bleeding in Anticoagulated Patients in the Emergency Care Setting
Conclusions: The introduction of alternative oral anticoagulants will require emergency procedures that differ in some respects from those currently in place for warfarin and it will be necessary for Emergency Medicine professionals to become familiar with these procedures. Clinical stabilization of the bleeding or at-risk patient remains the emergency physician’s priority.
Source: The Journal of Emergency Medicine - June 19, 2013 Category: Emergency Medicine Authors: Charles V. Pollack Tags: Clinical Reviews Source Type: research

Novel Antiplatelet and Anticoagulant Agents in the Cardiac Care Unit
This article reviews the pivotal studies of several novel antiplatelet (prasugrel and ticagrelor) and anticoagulant (dabigatran, rivaroxaban, and apixaban) agents. The clinical use of these drugs in cardiac intensive care is discussed, focusing on the management of acute coronary syndromes, ischemic stroke, atrial fibrillation, and venous thromboembolism.
Source: Cardiology Clinics - August 12, 2013 Category: Cardiology Authors: Vaani Panse Garg, Jonathan L. Halperin Source Type: research

Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
We report a 57-year-old man with a mechanical heart valve who experienced acute upper limb thromboembolism during dabigatran intake. Dabigatran might be inadequate for thromboprophylaxis after mechanical valve replacement. PMID: 24182477 [PubMed - in process]
Source: The Annals of Thoracic Surgery - November 1, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Kuwauchi S, Watanabe S, Abe K, Yamasaki M, Ito J, Kawazoe K Tags: Ann Thorac Surg Source Type: research

Novel Oral Anticoagulants and Atrial Fibrillation: Efficacy and Safety Considerations
Abstract For almost six decades, vitamin K antagonists (e.g., warfarin) were the only available oral drugs for the prevention of thromboembolism in patients with atrial fibrillation. Recently, novel oral anticoagulants that target thrombin (dabigatran) or activated factor X (rivaroxaban and apixaban) have successfully completed clinical development and received approval for stroke prevention in atrial fibrillation. Novel oral anticoagulants have been shown to be noninferior, or in some cases superior to warfarin in both safety and efficacy aspects. Their advanced pharmacological properties result to rapid, consisten...
Source: Drug Development Research - November 15, 2013 Category: Drugs & Pharmacology Authors: Stavros Apostolakis Tags: Clinical Commentary Source Type: research

New Trial Confirms Role For Pradaxa In Venous Thromboembolism
A new study helps support a role for  the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) in patients with venous thrombosis (VTE).  The RE-COVER II trial, published online in Circulation, confirms the finding of the earlier and highly similar RE-COVER trial, published in the New England Journal of Medicine in 2009, that dabigatran is as safe and effective as warfarin for the treatment of  deep vein thrombosis (DVT) and pulmonary embolism (PE). Dabigatran is currently approved only for the treatment of stroke prevention in patients with non-valvular atrial fibrillation.
Source: Forbes.com Healthcare News - December 18, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news